UK stock preview: Rolls-Royce, AstraZeneca, Argo Blockchain
Here are three LSE mainboard stocks to watch this week.
- Rolls-Royce (LON: RR) share price rallied 1.2% on Monday morning (13 September 2021), after it agreed to sell its stake in AirTanker Holdings
- AstraZeneca (LON: AZN) share price hits 8,212 pence following two positive phase 3 trial results
- Argo Blockchain (LON: ARB) share price dips in early trading, as it enters a new £18.05 million loan agreement
- Feeling bullish or bearish about these three stocks? Open an account with us to start trading them.
Rolls-Royce (LON: RR)
Rolls-Royce said on Monday it will sell its 23.1% shareholding in AirTanker Holdings Limited to Equitix Investment Management Limited for cash proceeds of £189 million.
This includes the repayment of shareholder loans and accrued and deferred interest of approximately £47 million.
The transaction is expected to complete by the end of the first quarter of 2022, subject to regulatory approvals.
There is no merger control condition in the deal. Proceeds will be used to reduce net debt. Remaining AirTanker shareholders have pre-emption rights over the Rolls-Royce shares and loan notes.
AirTanker Holdings Limited is a joint venture with Airbus, Babcock, and Thales.
Argo Blockchain (LON: ARB)
Argo Blockchain announced on Friday (10 September) that it has entered into a £18.05 million (US$25 million) loan agreement with a maturity date of 29 October 2021 with Galaxy Digital LP.
The loan agreement will use a portion of ARB’s Bitcoin holding as collateral.
Argo Blockchain’s outstanding loan with Galaxy Digital of £14 million (US$20 million) will be rolled into the new loan agreement, which will result in a total outstanding principal amount of £32.05 million (US$45 million).
The proceeds of the loan will be used, in conjunction with funds raised by the company previously, to continue the build out of the company's West Texas data centre and to meet its operating cash flow requirements.
The loan will also enable Argo to retain its current Bitcoin holding, whilst further expanding its mining operations, the company added in a press release.
AstraZeneca (LON :AZN)
AstraZeneca announced ‘positive results’ from the Poseidon Phase 3 trial last Thursday (09 September).
The results showed that AstraZeneca's Imfinzi (durvalumab) and tremelimumab, when added to platinum-based chemotherapy, ‘demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared to chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer’.
The biopharmaceutical giant also announced ‘positive high-level results’ from the Mandala and Denali Phase 3 trials of PT027 (albuterol/budesonide) for asthma patients.
The fixed-dose combination of both albuterol and budesonide demonstrated significant benefits for asthma patients, as compared with individual components of albuterol and budesonide.
Keen to take a shot at these FTSE 100 stocks?
Go short and long with spread bets, CFDs and share dealing on Rolls-Royce, AstraZeneca, Argo Blockchain and 16,000+ shares with the UK’s No.1 platform.* Learn more about trading shares with us, or open an account to get started today.
* Best trading platform as awarded at the ADVFN International Financial Awards and Professional Trader Awards 2019
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Live prices on most popular markets
You might be interested in…
Find out what charges your trades could incur with our transparent fee structure.
Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.
Stay on top of upcoming market-moving events with our customisable economic calendar.